- Home
- MD vs TSHA Comparison
MD vs TSHA Comparison
Compare MD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MD | TSHA |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MD | TSHA |
|---|---|---|
| Price | $19.33 | $4.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $20.00 | $10.56 |
| AVG Volume (30 Days) | 843.8K | ★ 2.1M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 62.50 |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $1,913,849,000.00 | $8,333,000.00 |
| Revenue This Year | $5.39 | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | $10.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.84 | $1.13 |
| 52 Week High | $24.99 | $6.02 |
Technical Indicators
Market Signals| Indicator | MD | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 44.58 |
| Support Level | $16.41 | $4.41 |
| Resistance Level | $22.47 | $5.39 |
| Average True Range (ATR) | 0.86 | 0.24 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 47.20 | 24.11 |
Price Performance
Historical ComparisonAbout MD Pediatrix Medical Group Inc.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.